Cytokinetics (CYTK) Competitors $36.69 -0.95 (-2.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$36.92 +0.23 (+0.64%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. GMAB, RDY, MRNA, QGEN, VTRS, ASND, VRNA, BBIO, BPMC, and ROIVShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Its Competitors Genmab A/S Dr. Reddy's Laboratories Moderna Qiagen Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Cytokinetics (NASDAQ:CYTK) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Do institutionals & insiders hold more shares of CYTK or GMAB? 7.1% of Genmab A/S shares are owned by institutional investors. 2.7% of Cytokinetics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, CYTK or GMAB? Cytokinetics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Does the media favor CYTK or GMAB? In the previous week, Cytokinetics had 1 more articles in the media than Genmab A/S. MarketBeat recorded 11 mentions for Cytokinetics and 10 mentions for Genmab A/S. Cytokinetics' average media sentiment score of 0.63 beat Genmab A/S's score of 0.58 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CYTK or GMAB? Cytokinetics presently has a consensus price target of $70.92, indicating a potential upside of 93.30%. Genmab A/S has a consensus price target of $37.80, indicating a potential upside of 73.55%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.88Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64 Which has higher earnings & valuation, CYTK or GMAB? Genmab A/S has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$18.47M237.24-$589.53M-$5.29-6.94Genmab A/S$3.12B4.48$1.14B$1.7612.38 Is CYTK or GMAB more profitable? Genmab A/S has a net margin of 35.11% compared to Cytokinetics' net margin of -3,201.47%. Genmab A/S's return on equity of 18.08% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-3,201.47% N/A -43.75% Genmab A/S 35.11%18.08%14.52% SummaryGenmab A/S beats Cytokinetics on 9 of the 17 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.38B$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-6.9417.6228.8523.79Price / Sales237.24309.96440.8796.30Price / CashN/A41.6335.0757.18Price / Book-31.908.488.255.54Net Income-$589.53M-$55.06M$3.25B$259.88M7 Day Performance-1.32%-3.99%-3.73%-4.67%1 Month Performance6.78%9.58%4.28%4.40%1 Year Performance-35.79%6.70%25.84%17.91% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics4.0902 of 5 stars$36.69-2.5%$70.92+93.3%-36.6%$4.38B$18.47M-6.94250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeGMABGenmab A/S3.6306 of 5 stars$21.69-0.9%$37.80+74.3%-23.2%$13.92B$3.12B12.322,682News CoverageUpcoming EarningsShort Interest ↑RDYDr. Reddy's Laboratories2.2908 of 5 stars$14.57+0.6%$16.95+16.4%-15.5%$12.16B$3.81B22.0727,811MRNAModerna4.4664 of 5 stars$30.97-0.9%$46.61+50.5%-70.7%$11.98B$3.24B-3.555,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownQGENQiagen3.2115 of 5 stars$48.06-0.6%$49.40+2.8%+12.1%$10.68B$1.98B120.495,765News CoverageUpcoming EarningsVTRSViatris2.2064 of 5 stars$8.90+0.2%$10.40+16.9%-26.3%$10.45B$14.74B-2.8132,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0689 of 5 stars$168.02-1.1%$223.07+32.8%+27.8%$10.39B$368.70M-26.751,017Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1478 of 5 stars$104.90flat$109.00+3.9%+365.2%$8.93B$42.28M-52.4530Positive NewsUpcoming EarningsShort Interest ↑BBIOBridgeBio Pharma4.712 of 5 stars$45.90-1.3%$61.50+34.0%+80.9%$8.72B$221.90M-13.00400Upcoming EarningsAnalyst ForecastBPMCBlueprint Medicines0.7174 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsROIVRoivant Sciences2.0643 of 5 stars$11.48+0.3%$16.50+43.7%+6.5%$7.80B$29.05M-45.92860Upcoming Earnings Related Companies and Tools Related Companies Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Qiagen Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
